Romilkimab

N/A

Report date: 2024/04/01 20:04:33

Base Information

Drug NameRomilkimab

Drug Alias NameSUB-33159SAR-156597

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionInterleukin-13 inhibitorsInterleukin-4 inhibitors

TargetsInterleukin-4Interleukin-13

Therapy Area/IndicationsScleroderma, SystemicIdiopathic Pulmonary Fibrosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBelgiumCanada +[25]

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesSanofi

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSanofi

Active IndicationsN/A

Inactive IndicationsScleroderma, SystemicIdiopathic Pulmonary Fibrosis

Other Information

ATC CodeN/A